Biersack Bernhard, Nitzsche Bianca, Höpfner Michael
Organic Chemistry Laboratory, University of Bayreuth, Bayreuth 95440, Germany.
Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin 10117, Germany.
Cancer Drug Resist. 2022 Jan 4;5(1):64-79. doi: 10.20517/cdr.2021.105. eCollection 2022.
Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes. Efficient anticancer drugs for the treatment of castration-resistant prostate cancer (CRPC) are sought, and approved HDAC inhibitors have shown promising results on the one hand and severe drawbacks on the other hand. Hence, ways to break the drug resistance mechanisms of existing HDAC inhibitors as well as the design of new promising HDAC inhibitors which can overcome the disadvantages of the classic HDAC inhibitors are of great importance. In this work, HDAC inhibitors with the potential to become a mainstay for the treatment of CRPC in the future as well as suitable combination treatments of HDAC inhibitors with other anticancer drugs leading to considerable synergistic effects in treated CRPCs are discussed.
表观遗传机制在癌症的发生和持续发展中起着重要作用，组蛋白去乙酰化酶（HDAC）抑制剂是有前景的针对表观遗传模式的抗癌药物。人们正在寻找用于治疗去势抵抗性前列腺癌（CRPC）的高效抗癌药物，已获批的HDAC抑制剂一方面显示出有前景的结果，另一方面也存在严重缺陷。因此，破解现有HDAC抑制剂耐药机制的方法以及设计能够克服经典HDAC抑制剂缺点的新型有前景的HDAC抑制剂至关重要。在这项工作中，讨论了未来有可能成为治疗CRPC主要药物的HDAC抑制剂，以及HDAC抑制剂与其他抗癌药物的合适联合治疗方案，这些联合治疗方案在治疗CRPC时可产生显著的协同效应。
Zotero 插件
